EP3579828A4 - Co-kristalle von substituierten glycinverbindungen und verwendungen davon - Google Patents

Co-kristalle von substituierten glycinverbindungen und verwendungen davon Download PDF

Info

Publication number
EP3579828A4
EP3579828A4 EP18751659.6A EP18751659A EP3579828A4 EP 3579828 A4 EP3579828 A4 EP 3579828A4 EP 18751659 A EP18751659 A EP 18751659A EP 3579828 A4 EP3579828 A4 EP 3579828A4
Authority
EP
European Patent Office
Prior art keywords
crystals
substituted glycine
glycine compounds
compounds
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18751659.6A
Other languages
English (en)
French (fr)
Other versions
EP3579828A1 (de
EP3579828B1 (de
Inventor
Guochuan Emil Tsai
Ching-Cheng Wang
Tien-Lan HSIEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SyneuRx International Taiwan Corp
Original Assignee
SyneuRx International Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SyneuRx International Taiwan Corp filed Critical SyneuRx International Taiwan Corp
Publication of EP3579828A1 publication Critical patent/EP3579828A1/de
Publication of EP3579828A4 publication Critical patent/EP3579828A4/de
Application granted granted Critical
Publication of EP3579828B1 publication Critical patent/EP3579828B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
EP18751659.6A 2017-02-13 2018-01-11 Co-kristalle von substituierten glycinverbindungen und verwendungen davon Active EP3579828B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/430,750 US9877942B1 (en) 2017-02-13 2017-02-13 Co-crystals of substituted glycine and uses thereof
PCT/CN2018/072186 WO2018145553A1 (en) 2017-02-13 2018-01-11 Co-crystals of substituted glycine compounds and uses thereof

Publications (3)

Publication Number Publication Date
EP3579828A1 EP3579828A1 (de) 2019-12-18
EP3579828A4 true EP3579828A4 (de) 2020-11-18
EP3579828B1 EP3579828B1 (de) 2025-03-26

Family

ID=61005084

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18751659.6A Active EP3579828B1 (de) 2017-02-13 2018-01-11 Co-kristalle von substituierten glycinverbindungen und verwendungen davon

Country Status (11)

Country Link
US (4) US9877942B1 (de)
EP (1) EP3579828B1 (de)
JP (2) JP2020507567A (de)
KR (1) KR20190118574A (de)
CN (1) CN110520117A (de)
CA (1) CA3051284A1 (de)
IL (1) IL268220B (de)
MX (1) MX393880B (de)
RU (1) RU2019128576A (de)
TW (1) TWI670058B (de)
WO (1) WO2018145553A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102403048B1 (ko) * 2016-06-13 2022-05-26 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산나트륨의 공-결정 및 그의 용도
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
CN113233976B (zh) * 2021-05-08 2021-11-16 广州萃普生物科技有限公司 一种没食子酸和氨基乙酸共晶及含有该共晶的美白膏霜
EP4419499B1 (de) 2021-10-20 2026-02-25 Purac Biochem B.V. Co-kristall von zitronensäure und glycin und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
EP1727520A2 (de) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M ILCZYSZYN ET AL: "Sarcosine-maleic acid (1:1) crystal: structure, 13C NMR and vibrational properties, protonation character", SPECTROCHIMICA ACTA. PART A: MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, vol. 59, no. 8, 1 June 2003 (2003-06-01), NL, pages 1815 - 1828, XP055732857, ISSN: 1386-1425, DOI: 10.1016/S1386-1425(02)00413-4 *
R. V. KRISHNAKUMAR ET AL: "Sarcosinium tartrate", ACTA CRYSTALLOGRAPHICA SECTION C. CRYSTAL STRUCTURE COMMUNICATIONS, vol. 57, no. 2, 15 February 2001 (2001-02-15), DK, pages 165 - 166, XP055732719, ISSN: 0108-2701, DOI: 10.1107/S0108270100012440 *
SCOTT A SOUTHERN ET AL: "Supporting Information NMR Investigations of Non-Covalent Carbon Tetrel Bonds. Computational Assessment and Initial Experimental Observation Contents", 10 December 2015 (2015-12-10), XP055732365, Retrieved from the Internet <URL:https://pubs.acs.org/doi/suppl/10.1021/acs.jpca.5b10848/suppl_file/jp5b10848_si_001.pdf> [retrieved on 20200921] *
SCOTT A. SOUTHERN ET AL: "NMR Investigations of Noncovalent Carbon Tetrel Bonds. Computational Assessment and Initial Experimental Observation", JOURNAL OF PHYSICAL CHEMISTRY. A, MOLECULES, SPECTROSCOPY,KINETICS, ENVIRONMENT AND GENERAL THEORY, vol. 119, no. 49, 10 December 2015 (2015-12-10), US, pages 11891 - 11899, XP055732362, ISSN: 1089-5639, DOI: 10.1021/acs.jpca.5b10848 *
See also references of WO2018145553A1 *

Also Published As

Publication number Publication date
US10765651B2 (en) 2020-09-08
US9877942B1 (en) 2018-01-30
TW201840308A (zh) 2018-11-16
JP2023082101A (ja) 2023-06-13
WO2018145553A1 (en) 2018-08-16
EP3579828A1 (de) 2019-12-18
MX393880B (es) 2025-03-24
US20180228754A1 (en) 2018-08-16
JP2020507567A (ja) 2020-03-12
US20190262299A1 (en) 2019-08-29
RU2019128576A3 (de) 2021-05-14
KR20190118574A (ko) 2019-10-18
CA3051284A1 (en) 2018-08-16
RU2019128576A (ru) 2021-03-15
EP3579828B1 (de) 2025-03-26
US20180228753A1 (en) 2018-08-16
US10328042B2 (en) 2019-06-25
IL268220B (en) 2022-04-01
US10328041B2 (en) 2019-06-25
CN110520117A (zh) 2019-11-29
JP7723991B2 (ja) 2025-08-15
MX2019009616A (es) 2019-10-14
TWI670058B (zh) 2019-09-01
IL268220A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
EP3487523C0 (de) Therapeutische anwendungen von cpf1-basierter genomeditierung
EP3595653A4 (de) Zusammensetzungen von plinabulin und verwendung davon
EP3773896A4 (de) Kontrollierte freisetzung von radionukliden
EP3922634C0 (de) Substituierte pyrrolizinverbindungen und verwendungen davon
UA37664S (uk) Елемент взуття
EP3548497A4 (de) Polymorphe von sepiapterin und salze davon
EP3602887A4 (de) Beenden von übertragungswiederholungen
EP3442420C0 (de) Vorhersage und überwachung von miktion
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
IL268731A (en) New uses of anti-sirpg antibodies
EP3592731A4 (de) Inhibitoren von malt1 und verwendungen davon
EP3484456A4 (de) Retard-darreichungsformen von pregabalin
EP3661919A4 (de) Substituierte kondensierte pyrimidinverbindungen und verwendungen davon
EP3639617A4 (de) Id-konfiguration von ran-bereich
EP3849527C0 (de) Formulierungen von cycloserinverbindungen und ihre verwendungen
EP3465427A4 (de) Choreografierte verteilte ausführung von programmen
EP3573620A4 (de) Zusammensetzungen zur behandlung von hypertonie
EP3849664C0 (de) Phenoxy-pyridyl-pyrimidinverbindungen und anwendungsverfahren
EP3683303A4 (de) Megamonas funiformis und verwendung davon
EP3226919C0 (de) Neutralisierung von gerüchen
EP3806844A4 (de) Dotaverbindungen und verwendungen davon
EP3491552A4 (de) Auslösung von anwendungsinformationen
EP3493823C0 (de) Postbiotika-basierte zusammensetzung zur behandlung von augenentzündungen
IL268220B (en) Co-crystals of substituted glycine compounds and their uses
HUE058153T2 (hu) Amid vegyületek és ezek alkalmazása

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017282

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20201016

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 307/62 20060101ALI20201012BHEP

Ipc: C07C 57/15 20060101ALI20201012BHEP

Ipc: A61K 31/198 20060101AFI20201012BHEP

Ipc: A61K 47/12 20060101ALI20201012BHEP

Ipc: A61P 25/00 20060101ALI20201012BHEP

Ipc: C07C 229/12 20060101ALI20201012BHEP

Ipc: C07C 57/12 20060101ALI20201012BHEP

Ipc: C07C 59/255 20060101ALI20201012BHEP

Ipc: A61P 25/18 20060101ALI20201012BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230628

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20241118

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018080466

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250627

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_29034/2025

Effective date: 20250618

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1778373

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250728

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250726

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018080466

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260211

26N No opposition filed

Effective date: 20260105

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260128

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260129

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260128

Year of fee payment: 9